Vadodara-based Sudeep Pharma on Friday, December 19, reported a mixed performance for the second quarter, with revenue growth offset by a drop in profitability.
The company’s net profit fell 6.15% year-on-year to ₹45.8 crore, compared with ₹48.8 crore in the same quarter last year.
EBITDA declined 11.2% to ₹55.5 crore from ₹63.5 crore a year earlier, while EBITDA margin narrowed to 34.1% from 42.7%, reflecting margin pressure during the quarter.
Revenue, however, rose 9.3% year-on-year to ₹162.7 crore, up from ₹148.8 crore in the corresponding period last year.
The results come shortly after Sudeep Pharma’s debut on Dalal Street. The company was listed on November 28, with shares opening at ₹733.95 on the BSE against an issue price of ₹593, while the stock debuted at ₹730 on the NSE.
Ahead of the listing, Sudeep Pharma’s shares were trading at a premium of about 20.4% in the unlisted market. Based on a grey market premium (GMP) of ₹121, the stock was expected to list around ₹714.
The company’s ₹895 crore initial public offering (IPO) was open for subscription between November 21-25 and saw strong investor demand. The issue was subscribed 93.72 times, attracting bids worth over ₹58,700 crore across nearly 29.86 lakh applications.
Shares of Sudeep Pharma ended higher on Friday, December 19, by 1.46% at ₹684 on the NSE.
Also Read: Suraj Estate acquires 2 parcels of land in Mumbai’s Bandra for new projects
